No. But they would more than likely hire someone to assess that before a buyout/partnership/merger. The study is FDA approved.
My belief all along has been the BioImage study is really what Abbott wants. Galectine 3 is the "carrot". Abbott has the money and resources to which they can put several new diagnostic products on their automated platform using information from the BioImage study.
From recent 10Q filing "We have exclusive rights to diagnostic inventions arising from our analysis of data generated from the BioImage Study, a proprietary observational and community-based cohort of over 6,800 individuals who have been followed since 2009. Baseline blood serum, plasma, and DNA and RNA samples collected from all participants have been stored and are available for our analysis. In addition, insurance claims data, including information regarding diagnoses, procedures, and therapies related to over 1,200 non-fatal cardiovascular events that were experienced by participants in the cohort over the more than four years since follow-up was initiated is available to us for data mining. We believe that this asset provides us with a unique and proprietary platform from which we may develop new diagnostic products."
Looks like we have another 10% owner
Yikes, calm down. Price has been low before. They had problems. They bounced. They will bounce again. You will see. No evidence has been presented to show otherwise except for speculation. GLTA
SD is holding up pretty well with the lawsuit and SEC garbage. Actually, quite impressive. I have seen other stocks tank 20 to 30 percent on news like this.
You nor anybody else on this message board will be asking any questions at earnings call. It is scripted and they will be putting out what they want to.
It was only only one study. Just one study. There are many that say otherwise.
Both are also recommended in the ACCF/AHA heart failure guideline .
Google the article below and see my point. New study came out saying Milk Is Bad For Bones and Heart.
Holy Cow! Study Suggests Milk Is Bad For Bones, Heart. Has The Medical Establishment Lied To Us?
Abbott Laboratories (ABT) entered the heart rhythm disorder market on Wednesday with the purchase of Topera Inc. as well as the option to buy Advanced Cardiac Therapeutics (ACT) .
Menlo Park, Calif.-based Topera works to develop electrophysiology technologies to improve treatment and diagnosis of atrial fibrillation, a common heart rhythm disorder. Under the terms of the agreement Abbott Park, Ill.-based Abbott will acquire outstanding equity of Topera for $250 million upfront with the possibility of future payments depending on performance milestones.
Topera's venture backers included New Enterprise Associates. The company raised $25 million Series C funding round in April 2013. Topera did not respond to a request for comment.
You are correct. He is just a disgruntle customer.
Yes. Updates once a week on Mondays. Sometimes not until later in the day.
Device Classification Name instrumentation for clinical multiplex test systems22
510(k) Number K133849
Device Name VANTERA CLINICAL ANALYZER
Original Applicant LIPOSCIENCE
2500 summer blvd.
raleigh, NC 27616
Original Contact suzette warner
Regulation Number 862.257023
Classification Product Code NSU24
Subsequent Product Codes CDT25 LBS26 MRR27
Date Received 12/19/2013
Decision Date 10/22/2014
Decision substantially equivalent (SESE)
Regulation Medical Specialty Clinical Chemistry
510k Review Panel Clinical Chemistry
FDA Review Decision Summary28
Reviewed by Third Party No
Combination Product No
Watch out for wash sale.
No way. Earnings are not going to be good. Last conference call they stated that they are losing orders/ not get new orders due to anticipated launch of automated version.
From recent 8-k filed 9-11-14
Employees affected by the Restructuring were notified on September 11, 2014 and are being provided with severance arrangements including outplacement assistance. The Company expects to complete the Restructuring during the third quarter of 2014.
As a result of the Restructuring, the Company expects to record one-time charges with respect to severance payments and benefits continuation, which are estimated to be approximately $0.3 million and are expected to be recorded in the third quarter of 2014.
This is now all about FDA clearance play.
As per Durbin's projections, Linn Energy cash distributions per unit will remain flat this year at $2.90, as compared to last year, but will gradually grow to $3.12 by 2018. However, other analysts have said that the dip in commodity prices may delay Linn Energy's growth of distributions paid to unit-holders.
Goldman Sachs has issued a neutral rating on Linn Energy with a twelve-month price target of $33.